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Background: Estrogen receptor alpha (ERa/ESR1) expression is regulated by alternative splicing. Its most frequently
detectable exon7 skipping isoform (ERaD7) is a dominant negative variant. Elevated expression of ERaD7 was
already detected in endometrial cancer (EC), while its potential prognostic significance has not been characterized
so far. Exon7 contains potential binding sites for the two functional splicing regulatory opponents, HNRNPG and
HTRA2-BETA1 known to trigger opposite effects on EC outcome.
This study served to elucidate the influence of HNRNPG and HTRA2-BETA1 on ERa exon7 splicing regulation and
the impact of ERaD7 concentration on type 1 EC outcome.
Methods: Functional in vitro experiments for HNRNPG and HTRA2-BETA1 in regard to the regulatory impact on
endogenous and exogenous ERaD7 splicing were performed. Additionally, real-time PCR determined mRNA levels
of ERaD7, HNRNPG and HTRA2-BETA1 in 116 type 1 EC patients.
Results: HNRNPG and HTRA2-BETA1 were found to be specific regulators of ERa exon7 splicing. While HTRA2-BETA1
promoted exon7 inclusion, HNRNPG antagonized this effect by inducing exon7 skipping (p = 0.004). ERaD7 was detected
in 71 out of 116 type 1 EC specimens. Statistical analyses revealed an inverse correlation between ERaD7 mRNA levels
and tumor grading (p = 0.029), FIGO stage (p = 0.033) as well as lymph node metastases (p = 0.032), respectively.
Furthermore, higher ERaD7 expression could be correlated to an improved disease-specific survival (p = 0.034).
Conclusions: Our study demonstrates antagonistic regulatory effects of HNRNPG and HTRA2-BETA1 on ERa exon7
splicing with potential impact on type 1 EC clinical outcome due to the consecutively variable expression levels of
the ERa isoform D7.
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Alternative splicingBackground
Endometrial cancer (EC) is the most common
gynecological malignancy in the western world and ac-
counts for 6% of all cancers in females [1]. The inci-
dence is estimated at 15–20 per 100,000 women per
year and it mainly affects peri- and postmenopausal
women, with 89% of cases occurring between 65–69
years of age [2,3]. EC is classified into two subtypes: the* Correspondence: elmar.stickeler@uniklinik-freiburg.de
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unless otherwise stated.estrogen-dependent type 1 with a background of excessive
exposure to estrogen unopposed by progesterone and the
estrogen-independent type 2 [4]. The lack of expression of
estrogen receptor alpha (ERa/ESR1) in type 1 EC was
found to be associated with poor differentiation of cancer
tissues and poor survival rates of EC patients, respectively
[5,6], supporting the hypothesis of a direct involvement of
ERa in EC tumorigenesis and progression. The expression
of ERa in normal or malignant endometrial tissue is sub-
jected to alternative splicing modulating its biological
function [7]. Several ERa splice variants with varying func-
tional differences were described. ERa isoform skippingral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gands, thus cannot stimulate estrogen-dependent gene
expression. ER variants skipping exon3 (ERaD3) or exon7
(ERaD7) are referred to as dominant negative, since they
interfere with normal ERa function, but cannot activate
regular ERa-mediated transcription [8]. ERaD5, a consti-
tutive mutant variant, is characterized by the capability to
activate transcription of ER-dependent genes without
binding to a ligand [8,9]. ERaD4, D5 and D7 were found
in EC and physiological endometrium [8]. The ERa exon7
skipping (ERaD7) isoform has been identified as the
most common phenotype in EC and breast cancer and
encodes for a protein lacking a portion of the hormone
binding domain [7,10]. This isoform represents a dominant
negative variant for both ERa and ER beta [7,10]. Induced
ERaD7 expression has been detected in the proliferative
compared to the secretory phase of endometrial tissue [11]
and also in well to moderately differentiated EC in com-
parison to poorly differentiated EC [12]. Besides these find-
ings and an influence on estrogen therapy sensitivity in
schizophrenic patients [13], the clinical significance of
ERaD7 in estrogen related cancer has not been elucidated
yet. Particularly the regulation of ERa mRNA processing is
not well understood, despite ERa exon 7 contains potential
binding sites for the two antagonistic splicing factors
HTRA2-BETA1 and HNRNPG (Figure 1). Recently our
group was able to link alternative splicing regulation to
EC tumor biology and clinical outcome [14] and identi-
fied HNRNPG and HTRA2-BETA1 as independent
prognosticators for EC type I progression-free survival.
Their antagonizing effects on alternative splicing pro-
cesses were directly reflected by their opposite effects on
EC biology.
Since alternative splicing is a pertinent control mech-
anism of gene expression with consecutive impact on
cellular processes like growth, apoptosis, invasion and
metastasis, respectively [15], we intended to elucidate
the potential regulatory influence of HNRNPG and
HTRA2-BETA1 on ERaD7 isoform expression profile in
type 1 EC, as well as its potential impact on clinico-
pathological characteristics and clinical outcome.
Methods
Patients and tissue samples
One hundred and sixteen consecutive patients with type
1 EC, who were treated at the Gynecological Hospital of
University Medical Center Freiburg between November
1997 and December 2005, were included in this study.
Median age of patients at the time of diagnosis was 65.
Patients receiving hormone replacement therapy prior to
surgery were excluded from the study. All patients under-
went hysterectomy, salpingo-oophorectomy and pelvic
lymphadenectomy (according to the current national
guidelines), and were properly staged according to theInternational Federation of Obstetrics and Gynecology
(FIGO) classification at the time. Tissue samples were
obtained at the time of surgery and collected in the
tumor tissue bank of Comprehensive Cancer Center
Freiburg (CCCF), Germany. The institutional review
board of CCCF and the local ethical committee of the
University Medical Center Freiburg approved and li-
censed the investigation protocol of this study (#32409).
All patients involved gave their informed consent prior
to inclusion in this study.
Paraffin embedded tissue specimen from hysterectomies
were obtained from the Institute of Pathology in University
Medical Center Freiburg. All haematoxylin-eosin stained
slides were reviewed by specially trained pathologists
(AzH, MOV). Histological classification was performed
according to the World Health Organization 2003 sys-
tem [16] into well differentiated (G1; n = 33), moderately
differentiated (G2; n = 59), and poorly differentiated (G3;
n = 24), respectively. Most patients neither had regional
lymph node metastases (81.9%) nor distant organ metas-
tases (68.1%). Cancer relapse was found in 17 patients
during follow up (14.7%). The time to relapse ranged
from 10–101 months after surgery. During follow up
nine patients with recurrence died from EC and one
from other cause. Seven recurrent patients were under
further follow up for an additional median time of
17 months (range 0.3-42 months, Table 1).
RNA extraction from paraffin embedded tissue and cDNA
synthesis
Each paraffin block used for RNA extraction was histo-
logically assessed with regard to tumor homogeneity to
guarantee a tumor cell content of more than 90%. Total
tissue RNA was extracted by using the High Pure RNA
Paraffin Kit (Roche, Mannheim, Germany) according to
the manufacturer’s protocol. RNA quality was controlled
by densitometry and accepted with A260/280 > 1.7.
RNA integrity was controlled on a 2100 Accessories &
Spare Parts system (Agilent Technologies, Waldbronn,
Germany). Prior to RT-PCR, each RNA sample was
digested with 2.0 U DNase I (Roche, Mannheim,
Germany) at 37°C for 45 min to eliminate genomic
DNA (gDNA) contamination. Four μg of purified RNA
were transcribed into cDNA using M-MLV reverse tran-
scriptase (Promega, Mannheim, Germany) and 10 pM
random hexamer primers (New England Biolabs GmbH,
Frankfurt, Germany) in a total volume of 50 μl.
Real-time quantitative PCR
Primers used for real time PCR were all designed in an
exon flanking way, except for ERa standard primers,
which were located in ERa exon1 (Additional file 1:
Table S1). Since ERa exon1 is constitutively transcribed
in all ERa mRNA isoforms, we used this amplicon to
Figure 1 Sequence analyses of ERa exon7 and potential mode of action of HNRNPG and HTRA2-BETA1 on ERa exon7 splicing regulation.
(A) Sequence analyses of ERa exon7. SS*: splice site; RS: arginine/serine rich domain of HTRA2-BETA1 (domain is required for protein-protein interaction
and recruiting of other splicing factors to exons). ERa exon7 sequence is shown between 5’SS and 3’SS. Its poly-pyrimidine tract sequence is
shown upstream of 5’SS and its 3’ intron sequence is shown downstream of 3’SS. Binding motifs of each splicing factor are stated out below
exon7 sequence and are indicated in original sequence, respectively. (B) The antagonizing effect of HTRA2-BETA1 to HNRNP I is shown, the
mechanism of this function is not clear. (C) The antagonizing effect of HNRNP G on HTRA2-BETA1 is shown. We propose that these two factors
antagonize each other in RNA binding in a concentration dependent manner.
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primer was located in conjunction part of ERa exon6
and 8 and the antisense primer in ERa exon8. This pri-
mer pair was designed to exclusively detect the ERaD7
isoform.
Samples of cDNA were heated to 95°C for 5 min
followed by 45 cycles of 95°C 20 s, 60°C 20 s, 72°C 20 s.
Expression of each gene was aggregated and then nor-
malized against housekeeping gene (HKG) RPS18. Rela-
tive expression levels were calculated using the followingformula: Ratio = E target
ΔCt target (control –target) / E HKG
ΔCt HKG (control - HKG) [17]. All PCR analyses were per-
formed in triplicates, while arithmetic mean of data
served as base for subsequent statistical analysis.
Plasmid construction
Full length of HNRNPG cDNA (NCBI Reference Sequence:
NM_001164803.1) was subcloned into the mammalian
expression vector pCMV-Script (Stratagene, Agilent
Technologies, Waldbronn, Germany). The pCMV-Script







Enodometrioid adenocarcinoma 102 (87.9%)

































Chemotherapy & radiotherapy 6 (5.2%)
Unknown 4 (3.4%)
Recurrent EC and outcome
EC recurrent 17 (14.7%)
EC related death 9 (7.8%)
Table 1 Clinico-pathological features of patient cohort
(Continued)
Other related death 1 (0.9%)
Further-on follow up 7 (6.0%)
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(Fermentas, St. Leon-Rot, Germany) at 37°C for 1 hour.
After digestion, blunt vector ends were dephosphory-
lated by Antarctic phosphatase (New England Biolabs,
Frankfurt, Germany). HNRNPG full length cDNA was
phosphorylated by Polynucleotide Kinase (New England
Biolabs, Frankfurt, Germany). Dephosphorylated vector
and phosphorylated insert were purified with High
Pure PCR product purification Kit (Roche, Mannheim,
Germany) prior to ligation. Blunt end ligation was achieved
by using T4 DNA ligase (Fermentas, St. Leon-Rot, Germany)
at 4°C overnight. HTRA2-BETA1 expression plasmid was
kindly provided by Prof. Stefan Stamm (Stamm’s Lab at
Department of Molecular & Cellular Biochemistry,
University of Kentucky, Lexington, U.S.A.). HNRNPG
and HTRA2-BETA1 shRNA plasmids were obtained
from Santa Cruz (Santa Cruz Biotechnology Inc., Santa
Cruz, U.S.A.).
ERa exon7 minigene construction
ERa exon7 together with part of its upstream and down-
stream intron sequence was subcloned into pCMV-INS
plasmid. pCMV-INS plasmid contained insulin (INS) gene
exon2 and exon3. Vector plasmid was digested between
INS exon2 and exon3 with Pfl23II restriction enzyme
(Fermentas, St. Leon-Rot, Germany). Vector dephos-
phorylation, insert phosphorylation and ligation were
conducted as described above. The amount of insert for
ligation was calculated according to following formula:
Insert mass (ng) = 6× Insert length (bp) / Vector length
(bp) × Vector mass (ng). Plasmids were subsequently veri-
fied by sequence analyses (GATC BIOTECH, Konstanz,
Germany). Plasmid-relevant PCR products are shown in
Figure 2D.
Cell culture and transfection
Human EC cell line Ishikawa and human cervical cancer
cell line HeLa were maintained in GIBCO® DMEM
media (Invitrogen, Karlsruhe, Germany) supplemented
with 10% fetal bovine serum (Invitrogen, Karlsruhe,
Germany). Cells (150 × 103/well) were seeded in 6-well
plates (Ø 30 mm) 24 hours before transfection, leading
to a cell confluency of 60-70%. Plasmid DNA was trans-
fected into cells via polyethylenimine (PEI) transfection.
Empty pCMV-Script vector was used as a transfection
control (Additional file 1: Table S2).
Endogenous ERa exon7 splicing pattern were detected
in differently treated Ishikawa cells after single HNRNPG
Figure 2 Functional implications of HNRNP G and HTRA2-BETA1 in EC in vitro. (A) HNRNP G and HTRA2-BETA1 protein expression in Ishikawa
cells transiently transfected with expression and knock-down plasmids; (−) shRNA and (+) expression plasmid for HNRNPG and HTRA2-BETA1; (C) control:
empty pCMV-plasmid. HKG:Beta-Actin. Western blot. (B) Influence of HTRA2-BETA1 and HNRNPG mRNA-levels on endogenous ERa-exon7 mRNA splicing. (C)
cells transfected with: control: empty pCMV-plasmid; (HTRA2-BETA1+) HTRA2-BETA1-expression-plasmid; (HTRA2-BETA1 −) HTRA2-BETA1-shRNA;
(HNRNPG +) HNRNPG-expression-plasmid; (HNRNPG −) HNRNPG-shRNA. RT-PCR. (C) HNRNPG, HTRA2-BETA1, ERa-standard and ERa-exon6 mRNA
expression in differently treated Ishikawa cells. (C) control:pCMV-plasmid; (HTRA2-BETA1 +) HTRA2-BETA1-expression-plasmid; (HTRA2-BETA1−)
HTRA2-BETA1-shRNA; (HNRNPG +) HNRNPG-expression-plasmid; (HNRNPG −) HNRNPG-shRNA. HKG:RPS18. RT-PCR. (D) Exogenous level of ERa-exon7
splicing pattern. Influence of overexpression (+) and knock-down (−) HNRNPG and HTRA2-BETA1 on alternative ERa-exon7 minigene expression. In
untransfected control cells, the reporter gene was alternatively spliced into 4 isoforms, two precisely spliced isoforms are exon7-skipping (137bp) and
exon7-inclusion (321bp). Two lariat containing isoforms are: one containing a part of intron sequence between INS-exon2 and -3 (210bp), another
containing an additional pseudo-exon from exon7 5’ intron sequence (544bp, all four isoforms were verified by sequencing). RT-PCR. (E,F) ERa exon7
alternative splicing regulation by HTRA2-BETA1 and HNRNPG in Ishikawa cells. (E) ERa-exon7 skipping/inclusion ratio; (F) HNRNPG/HTRA2-BETA1 ratio in
differentially treated Ishikawa cells. (C) control:pCMV-plasmid; (HTRA2-BETA1 +) HTRA2-BETA1-expression-plasmid; (HTRA2-BETA1 −) HTRA2-BETA1
shRNA; (HNRNPG +) HNRNPG-expression-plasmid; (HNRNPG −) HNRNPG-shRNA. (G) ERa exon7 skipping/inclusion mRNA ratio difference between
HTRA2-BETA1overexpression and HNRNPG overexpression group. (HTRA2-BETA1 +) HTRA2-BETA1 overexpression; (HNRNPG +) HNRNPG overexpression;
**ERa exon7 skipping/inclusion ratio between the two groups was statistically significant p= 0.004. PCR-based tests originate on arithmetic mean of triplicate
analyses. Student-T-test was applied for data shown in E-G, while statistical significance was assumed at p<0.05 at the two-sided test. Representative gel images
in B-D demonstrate one out of three repeats.
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splicing pattern were analyzed in co-transfected HeLa
cells with the ERa exon7 minigene as reporter.
RNA and protein extraction
Total cellular RNA and protein were extracted 48 hours
after transfection applying TRIzol® reagent (Invitrogen,
Karlsruhe, Germany) isolation protocol. Before RT-PCR,
DNase I digestion was used to exclude gDNA contamin-
ation as well.
Western blot for hnRNP G and HTRA2-BETA1 detection
Western blot analyses were performed to evaluate the
HNRNPG and HTRA2-BETA1 expression plasmid as
well as shRNA plasmid efficacy after transfection. The
immune complexes were visualized by an ECL assay
(Figure 2A). Rabbit polyclonal IgG HNRNPG (RBMX)
antibody (sc-48796, Santa Cruz Biotechnology, Inc.) and
rabbit polyclonal IgG HTRA2-BETA1 antibody [18] (pro-
vided by Prof. Stefan Stamm, (Stamm’s Lab, Department of
Molecular & Cellular Biochemistry, University of Kentucky,
Lexington, U.S.A.)) were used.
ERa exon7 detection in transfected Ishikawa and HeLa cells
The primer design for ERa exon7 amplification (amplicon
ranging from exon6 to exon8) allowed the detection of
both exon7 inclusion and skipping isoforms. Since ERa
exon6 is also subject to alternative splicing, ERa exon6 as
well as ERa standard (primers located in exon1) PCR as-
says were used as ERa transcript level control for differ-
ently transfected cells (primer sequences: Additional file 1:
Table S1). Conditions for ERa standard, exon 6 and exon7
PCR were as follows: 95°C 5 min, followed by 35 cycles
95°C 20 s, 60°C 20 s, 72°C 20 s.
The primers for the pCMV-INS based were comple-
mentary to INS exon 2 and exon 3, respectively and de-
signed to detect different splicing pattern of ERa exon7
minigene after co-transfection. Post co-transfection PCR:
95°C 5 min, followed by 45 cycles 95°C 20 s, 60°C 15 s,
72°C 45 s. PCR products were separated by gel electro-
phoresis and quantitative analysis was conducted by ap-
plication of imageJ software (http://rsbweb.nih.gov/ij/).
Sequence analysis
PCR products of endogenous and exogenous ERa exon7
alternatively spliced isoforms were subcloned into the
CloneJET™ PCR Cloning Kit (Fermentas, St. Leon-Rot,
Germany). PCR products of the HNRNPG expression plas-
mid, ERa exon7 minigene and ERa exon7 isoform PCR
products were sequenced by GATC BIOTECH (Konstanz,
Germany). Furthermore, all PCR amplicons produced in
different analyses were subject to verification via sequence
analysis. Sequencing results were compared with NCBI ref-
erence sequences (http://www.ncbi.nlm.nih.gov/).Statistical analyses
The expression levels of ERa were categorized as follows
(normalization against RNA of HKG RPS18) for con-
secutive quantification:
group 0: no ERa standard mRNA detectable; group 1:
ERa standard mRNA amount ≤0.81; group 2: ERa stand-
ard mRNA amount >0.81, due to the mean mRNA level
within ERa standard positive samples being 0.81. ERaD7
mRNA levels were defined as group 0: no ERaD7 mRNA
detectable; group 1: ERaD7 mRNA amount ≤0.80; group
2: ERaD7 mRNA amount >0.80, due to the mean ERaD7
mRNA level within ERaD7 positive ones being 0.80.
The D7 real time PCR results were analyzed in regards
to potential correlations with clinicopathological data by
Spearman’s correlation test. Univariate and multivariate
analyses were performed with Kruskal-Wallis H test and
general linear model, respectively. When performing sur-
vival analyses, the records of patients who died of EC were
considered to be uncensored; the records of patients who
were alive during follow up or who died from other dis-
eases were considered to be censored. Univariate analyses
of disease-specific survival and progression-free survival
were performed with Kaplan-Meier life-table curves
and compared using the Log rank test. Multivariate
prognostic analyses used multivariate Cox regression
test in a forward step wise manner [19]. Student T test
was used for RT-PCR results analyses. Statistical signifi-
cance was assumed at p ≤ 0.05 at the two-sided test
(SPSS 15.0 software, SPSS Inc.).
Results
HTRA2-BETA1 and HNRNPG as antagonistic regulators of
ERa exon7 splicing
Functional experiments in Ishikawa endometrial cancer
cells with transient transfection of HTRA2-BETA1 and
HNRNPG expression plasmids revealed that endogenous
exon7 inclusion was specifically induced by HTRA2-
BETA1. In contrast, HNRNPG acted as a splicing inhibitor
with induced levels of exon7 skipping (Figure 2B). As a
consequence, the exon7 skipping/inclusion ratio was sig-
nificantly higher in HNRNPG in comparison to HTRA2-
BETA1 overexpression (Figure 2B, C, F, Additional file 1:
Table S4). However, expression of endogenous ERa
standard as well as ERa exon6 was not affected by the
two splicing factors (Figure 2C).
Employing an ERa exon7 reporter gene the findings of
a high specificity of the HTRA2-BETA1 and HNRNPG
effects were confirmed on the in vitro level (Figure 2D).
Induced ERaD7 expression is correlated to favorable
clinico-pathological parameters
In type 1 EC, ERa mRNA expression could be detected
in 87 samples (75%) of which 71 (61.2% of the complete
cohort) expressed the ERaD7 isoform.
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Methods, statistical analyses) both ERa standard and
ERaD7 mRNA levels were found to be inversely corre-
lated to grading (−0.317, p = 0.001) and FIGO stage
(−0.222, p = 0.033). Furthermore, increased ERaD7
mRNA levels were detected in tumors without regional
lymph node metastases (correlation coefficient = −0.206,
p = 0.032, Table 2). The observed differences in ERaD7
mRNA levels between well to moderately and poorly dif-
ferentiated cancers, FIGO stage I/II and III/IV, as well as
lymph negative and positive groups were all statistically
significant (p = 0.030, p = 0.034, p = 0.032, respectively,
Kruskal-Wallis Test, Table 3).
The ratio of ERaD7 to ERa standard is inversely related to
HTRA2-BETA1 expression
We chose real-time PCR quantification of ERaD7 iso-
form since this methodical approach results in more ac-
curate data on mRNA quantity. Real-time qPCR runs as
a robust and reliable standard procedure in our lab and
all randomly applied re-checks of qPCR products via
classic gel electrophoresis accounted for the desired
amplicons. Since our real-time PCR sense primer for
ERaD7 detection was designed to be complementary to
the conjunction of exon6 and 8, the calculation of ERaD7
mRNA level might be influenced by exon6 skipping, even
though there were only 8 samples positive for ERaD6.
To overcome this problem, we also calculated the ex-
pression ratio of ERaD7 in total ERa transcript amount
(ratio = ERaD7 mRNA level/ERa standard mRNA level)
and performed additional analyses. Significant differences
in the ratio between moderately and poorly differentiated,
FIGO stage III/IV as well as lymph node positive tumorsTable 2 Correlation of ERa standard and ERaD7 expression w
(Spearman’s correlation test)
Spearman’s FIGO Grade
(I/II vs III/IV) (1/2 vs 3)
ERα standard correlation −0222* −0.317**
coefficient
p (2-tailed) 0.033 0.001
N 92 116
ERαΔ7 correlation −0.223* −0.203*
coefficient
p (2-tailed) 0.033 0.029
N 92 116
ERαΔ7/standard correlation −0.251* −0.227*
coefficient
p (2-tailed) 0.016 0.014
N 92 116
T = Primary tumor; LN = lymph node metastasis; M=distant organ metastasis; L = lympha
the 0.05 level (2-tailed); ** = significant at the 0.001 level.(p = 0.015, p = 0.016. p = 0.016, respectively, Kruskal-
Wallis Test, Table 3) could be detected. Like the ERaD7
mRNA level, its relative expression ratio in total ERa was
also found to be associated with FIGO stage (R2 = 2.311,
p = 0.006, Additional file 1: Table S3). Furthermore, we
were able to detect an inverse correlation of ERaD7/ERa
standard ratio with HTRA2-BETA1 mRNA levels (correl-
ation coefficient = −0.198, p = 0.034, Table 2).
Higher ERaD7 mRNA levels are associated with improved
survival
Expression of ERa and its isoform ERaD7 were also ana-
lyzed in regards to patient outcome. Besides the earlier
mentioned categorization in groups 0–2 an additional
ERaD7 expression ratio was defined with two groups:
ERaD7/ERa standard mRNA ratio >0.5 and ERaD7/ERa
standard mRNA ratio ≤0.5.
Univariate survival analyses suggested that patients
with higher ERa expression had a better progression-
free survival (p = 0.045, Figure 3). Patients with high
ERaD7 mRNA levels (group 2) displayed a better cumu-
lative survival rate in comparison to level 1 and level 0,
respectively. This difference correlated with improved
disease-specific survival (p = 0.034, Figure 3). In line with
these findings higher ERaD7/ERa standard ratio were
correlated to an improved progression-free survival rate
(p = 0.037, Figure 3).
When performing Cox regression test, data were ad-
justed for ERa and ERaD7 mRNA level groups, FIGO
stage (I/II versus III/IV), tumor differentiation grade
(G1/G2 versus G3), lymph node metastasis and distant
organ metastasis, respectively. The latter two factors
were entered as categorical variables defined as negative,ith clinico-pathological features and HTRA2-BETA1
T LN M L hTra2β1
(P vs N) (P vs N) (P vs N) mRNA
N.S N.S N.S N.S −0.214*
N.S N.S N.S N.S 0.022
116 109 86 50 115
N.S −0.206* N.S −0.332* −0.168
N.S 0.032 N.S 0.019 0.073
116 109 86 50 116
N.S −0.232* N.S −0.407** −0.198**
N.S 0.015 N.S 0.003 0.0034
116 109 86 50 116
ngiosis; P = positive; N = negative; p = p value; N.S =Not significant; * = significant at
Table 3 ERaD7 mRNA level in correlation to different parameters (Kruskal-Wallis Test)
FIGO Grade LN L hTra2β1
(I/II vs III/IV) (1/2 vs 3) (P vs N) (P vs N)
ERα standard mean rank 50.97 vs 38.87 63.74 vs 37.33 56.59 vs 44.21 29.25 vs 22.04 62.31 vs53.61
p (2-tailed) 0.034 0.001 0.168 0.075 0.159
ERαΔ7 mean rank 50.90 vs 39.00 61.77 vs 45.26 57.42 vs 38.57 30.23 vs 21.13 62.62 vs 53.30
p (2-tailed) 0.034 0.030 0.032 0.020 0.123
ERαΔ7/standard mean rank 51.48 vs 38.00 62.17 vs 43.67 57.73 vs 36.46 31.31 vs 20.13 72.52 vs 49.00
p (2-tailed) 0.016 0.015 0.016 0.004 0.000
Figure 3 Kaplan-Meier survival curves for disease-specific survival and progression-free survival in regard to ERa standard and ERaD7
expression (group 0: no ERa standard mRNA detectable; group 1: ERa standard mRNA amount ≤0.81; group 2: ERa standard mRNA
amount >0.81, due to the mean mRNA level within ERa standard positive samples being 0.81. ERaD7 mRNA levels were defined as group 0:
no ERaD7 mRNA detectable; group 1: ERaD7 mRNA amount ≤0.80; group 2: ERaD7 mRNA amount >0.80, due to the mean ERaD7 mRNA level within
ERaD7 positive ones being 0.80.) Log rank test.
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ation grade was identified as an independent prognosti-
cator for disease-specific survival, but ERa standard
mRNA expression was also identified as an indicator for
progression-free survival (Additional file 1: Table S3),
respectively.
Discussion
ERa regulates gene expression either by binding to estro-
gen response elements (ERE) or through ERE-independent
signaling (such as interactions with other transcription
factors like AP-1, SP1, NF-KB) [20-24]. Those down-
stream effects from aberrant ERa regulation provoke
changes in cellular function toward carcinogenesis. ERa as
a prognosticator for EC has been studied for its potential
influence on EC carcinogenesis. Horvath and colleagues
reported a decrease of wild type ERa and an increase of
ERaD7 isoform in estradiol treated EC tissue correlated
with an estradiol-resistant growth phenotype with no
growth rate change in comparison to controls [25]. These
findings together with others suggested a competitive ef-
fect of ERaD7 on its wild type in determination of cellular
hormone sensitivity [10,13]. Our study revealed an ERaD7
induction in type 1 EC and a correlation of its expression
level to the FIGO stage. Higher ERaD7 mRNA levels were
statistically significant correlated to an improved outcome
with a better disease-specific survival as demonstrated by
Kaplan-Meier survival curves (p = 0.034, Log-rank test,
Table 3). The univariate survival analyses demonstrated a
significant improved progression-free survival, defined as
incidence of local or distant recurrence, for total ERa ex-
pression, which was already published in the literature. For
ERaD7 a significant improved disease-specific survival, ex-
cluding all non-endometrial cancer related deaths, was also
seen. In line with these observations the ratio of ERaD7/
total ERa transformed into an improved progression-free
survival (p = 0.037) in this EC subtype.
ERaD7 origins from an out-of-frame exon deletion
that disrupts the ligand binding domain. Therefore sup-
posedly functions as a dominant negative repressor of
ERa transactivating properties [8]. Jazaeri et al. mention
that ERa variants, e.g. ERaD7, may account for growth
advantages in variant expressing cells under selective pres-
sure caused by estrogens or anti-estrogens [8]. Further-
more they point out, that according to the heterodimer
activity of ERa standard (wild-type) and variants, even
small quantities of alternatively spliced isoforms can have
a major effect on cell physiology [8]. We hypothesize, that
the correlation of elevated ERaD7 expression and im-
proved outcome in type 1 EC is based on the diminished
cellular estrogen sensitivity. Malfunctioning estrogen
receptor a-dependent transcription and associated
tumor progression signaling pathways could account for
the decrease of malignant behavior of ERaD7 expressingendometrial tumors. Furthermore, the pharmacological
effect of anti-estrogens, e.g. tamoxifen, might be also re-
duced by ERaD7-mediated ERa resistance in regard to
transcriptional activation of target genes. Functional stud-
ies demonstrated increased cellular levels of ERaD7 in re-
sponse to both estrogen and tamoxifen exposure [25].
Interestingly, long-term exposure to either unopposed
estrogen, e.g. hormone replacement therapies or tam-
oxifen treatment are major risk factors for EC [26].
So far the underlying mechanisms of regulation of ERa
exon7 expression were not understood. Gotteland and
colleagues described different ERa mRNA isoforms in
physiological and malignant breast tissues, suggesting
this phenomenon could be caused by alternative splicing,
independent from cell transformation [27]. The analyses
of the ERa exon7 sequence strongly supported the hy-
pothesis of alternative splicing regulation (Figure 1A, B).
Both, its 5’ polypyrimidine tract and 3’ intron sequence
contain HNRNP I binding motifs [28-30]. It is known that
HNRNP I represses exon splicing by looping out exons
between its binding motifs, which has been found in
various kinds of tissues (reviewed in [31-34]). This
might explain why ERaD7 is the most frequently detectable
isoform of ERa. It is well known that HTRA2-BETA1
preferentially promotes splicing of exons with GAA-rich
domains in a concentration dependent manner [35,36].
The ERa exon7 sequence expresses two potential HTRA2-
BETA1 binding motifs which could explain why
HTRA2-BETA1 is promoting exon7 splicing on both,
the endogenous as well as the exogenous level. HNRNPG
is a known antagonizing factor of HTRA2-BETA1 activity
in mRNA processing [37]. In our in vitro analyses, the
expected antagonizing effects of HNRNPG on HTRA2-
BETA1 became evident by the specific induction of ERa
exon7 skipping (Figure 2B, D, G). Since exon7 contains
the preferential HNRNP G binding sites AAGU and CC
(A/C) [37,38] we hypothesize in accordance to other
groups [37], that both splicing factors HTRA2-BETA1
and HNRNP G exhibit their antagonistic effects on ERa
exon7 splicing by a concentration dependent competi-
tion (Figure 1C).
In previous studies, we analyzed ERa alternative splicing
pattern in EC in regard to skipped exons or exon cassettes
by use of combinatory primer pairs for PCR. Our prior
analyses did not identify exon7/exon 8 skipping in EC
samples, in detail: no EC cell line or EC tissue specimen
(>20 specimen tested) exhibited this splicing possibility
(data not shown).
Carcinogenesis is characterized by complex alterations in
a magnitude of cellular mechanisms. Aberrant alternative
splicing has a high impact on cellular processes that lead
to cancer or promote cancer progression, including resist-
ance to apoptosis and promotion of invasion, metastasis
and angiogenesis, respectively [15]. Our previous study
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opposite effects on EC prognosis: a simultaneous higher
level of HTRA2-BETA1 protein nuclear expression as well
as mRNA is correlated to poor disease-specific as well as
progression-free survival. On the contrary, high expression
levels of nuclear HNRNP G protein and mRNA are associ-
ated with an improved clinical outcome in the same patient
cohort. In our present study, we detected an inverse correl-
ation between ERaD7 expression ratio and HTRA2-BETA1
mRNA level. Furthermore, our in vitro experiments
demonstrated that HTRA2-BETA1 works as a splicing
enhancer for ERa exon7, while HNRNP G acts as an op-
ponent of HTRA2-BETA1 by antagonizing the HTRA2-
BETA1 effect on ERa exon7 inclusion.
These functional data are in line with our observation
regarding the correlation of ERaD7 expression and the
clinicopathological features as well as outcome data of
patients with type 1 EC.
Conclusions
The present study strongly supports our recently published
hypothesis, that increased HNRNPG levels are associated
with improved clinical outcome. This is due to the fact,
that we were able to identify this nuclear protein as a spe-
cific regulator towards high levels of ERaD7 expression.
However, the best proof for this theory is given by the fact
that increased expression of ERaD7 was also characterized
as a prognosticator towards an improved clinical outcome.
The important biological role of ERa in estrogen-
dependent EC carcinogenesis is further supported by
our study.
Taking all evidence into account, we hypothesize that
expression pattern of splicing factors have profound ef-
fects on cancer cell biology. Our present study provides
a new evidence for the pivotal impact of aberrations in
alternative splicing pattern in carcinogenesis.
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